dinitroglycerol : A nitroglycerol carrying two nitro groups at unspecified positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 79076 |
| CHEMBL ID | 1635 |
| CHEBI ID | 18898 |
| SCHEMBL ID | 462502 |
| MeSH ID | M0498946 |
| Synonym |
|---|
| 1-01-00-00272 (beilstein handbook reference) |
| 8542i4ge54 , |
| unii-8542i4ge54 |
| 1,2-dinitroglycerin |
| glycerol, 1,2-dinitrate |
| 1,2-dinitroglycerol |
| C0062 |
| propanetriol 1,2-dinitrate |
| 1,2,3-propanetriol, 1,2-dinitrate |
| brn 1788957 |
| glyceryl 1,2-dinitrate |
| glyceryl-1,2-dinitrate |
| dinitroglycerol |
| 621-65-8 |
| 3-hydroxypropane-1,2-diyl dinitrate |
| CHEBI:18898 , |
| 1,2-glyceryl dinitrate |
| CHEMBL1635 |
| (1-hydroxy-3-nitrooxypropan-2-yl) nitrate |
| AKOS006272810 |
| 1,2,3-propanetriol, dinitrate |
| einecs 248-402-7 |
| 27321-62-6 |
| dinitroglycerine |
| glycerol dinitrate |
| 1,2,3-propanetriol,1,2-dinitrate |
| GFVHBTOOPNJKLV-UHFFFAOYSA-N |
| 1,2-dinitroglycerin [usp-rs] |
| SCHEMBL462502 |
| FT-0749102 |
| DTXSID30875566 , |
| 2,3-bis-nitrooxy-propan-1-ol |
| Q27109098 |
| dtxcid301013687 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The goal of this study was to examine the pharmacokinetic properties of these metabolites in rats." | ( Pharmacokinetic studies of the nitroglycerin metabolites, 1,2- and 1,3- glyceryl dinitrates, in the rat. Benet, LZ; Gumbleton, M; Labisch, C; Lau, DT, 1991) | 0.28 |
| " Additionally, for practical use of the transdermal system, a simple pharmacokinetic model to describe plasma 1,3-GDN levels after percutaneous (p." | ( Percutaneous absorption of 1,3-dinitroglycerin and a trial of pharmacokinetic analysis. Iwaki, M; Kanokogi, A; Ogiso, T; Terao, Y, 1990) | 0.28 |
| " The purpose for this present study was to determine the pharmacokinetic parameters of nitroglycerin and the dinitrate metabolites after multiple intravenous infusions of nitroglycerin in healthy volunteers." | ( Dose dependent pharmacokinetics of nitroglycerin after multiple intravenous infusions in healthy volunteers. Benet, LZ; Noonan, PK; Williams, RL, 1985) | 0.27 |
| " For each subject parametric pharmacodynamic modeling was performed with simultaneous analysis utilizing the DBP vs." | ( Simultaneous pharmacodynamic modeling of the non-steady-state effects of three oral doses of 1,3-glyceryl dinitrate upon blood pressure in healthy volunteers. Benet, LZ; Gumbleton, M, 1993) | 0.29 |
| "To construct a pharmacokinetic (PK) model and to determine population PK parameters of nitroglycerin (GTN), 1,2-dinitroglycerin (1,2-GDN), and 1,3-dinitroglycerin (1,3-GDN)." | ( Novel pharmacokinetic modelling of transdermal nitroglycerin. Auclair, B; Ducharme, MP; Ngoc, AH; Sirois, G, 1998) | 0.3 |
| "The purpose of this study was to assess the ability of our previously constructed pharmacokinetic (PK) model to describe nitroglycerin (GTN), 1,2-dinitroglycerin (1,2-GDN), and 1,3-dinitroglycerin (1,3-GDN) plasma concentrations after a single-dose application of a GTN transdermal matrix delivery system." | ( Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system. Auclair, B; Ducharme, MP; Ngoc, AH; Sirois, G, 1998) | 0.3 |
| " The ratios of the Cmax were within said limits for the signal metabolite 1,2-GDN and only slightly below (0." | ( Bioavailability and pharmacokinetic profile of glyceryl trinitrate and of glyceryl dinitrates during application of a new glyceryl trinitrate transdermal patch. Caplain, H; Gualano, V; Rovati, LC; Santoro, A; Setnikar, I, 2000) | 0.31 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The relative bioavailability of the tablets in comparison with the oral solution was 70 per cent based on metabolite concentrations." | ( Pharmacokinetics of nitroglycerin and its metabolites after administration of sustained-release tablets. Curry, SH; Green, P; Kwon, HR, 1992) | 0.28 |
| " Bioavailability of oral GTN (0." | ( Pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its two dinitrate metabolites in conscious dogs. Benet, LZ; Lee, FW; Metzler, CH; Salmonson, T, 1990) | 0.28 |
| " The bioavailability of 1,3-GDN after gel base systems with and without a membrane was relatively high." | ( Percutaneous absorption of 1,3-dinitroglycerin and a trial of pharmacokinetic analysis. Iwaki, M; Kanokogi, A; Ogiso, T; Terao, Y, 1990) | 0.28 |
| "The pharmacokinetics and bioavailability of nitroglycerin (GTN) and its metabolites, 1,2-glyceryl dinitrate (1,2-GDN) and 1,3-glyceryl dinitrate (1,3-GDN), were compared after a single 14-hour application of Transderm-Nitro (Ciba-Geigy, Summit, NJ), Nitrodisc (GD Searle, Chicago, IL), and Nitro-Dur II (Key Pharmaceuticals, Kenilworth, NJ) systems to 18 healthy male subjects on 3 separate occasions." | ( Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. Chan, K; Cipriano, A; Joshi, JC; Morgan, JM; Piraino, AJ; Redalieu, E; Sun, JX, 1995) | 0.29 |
| "In the course of this study both the bioavailability and main pharmacokinetic parameters of the glyceryl trinitrate (GTN, CAS 55-63-0) metabolites 1,2 and 1,3-glyceryl dinitrate (1,2-GDN and 1,3-GDN) were to be determined following transdermal application of a glyceryl trinitrate test patch (Deponit 5) and an already marketed reference patch." | ( Bioequivalence evaluation of the metabolites 1,2 and 1,3-glyceryl dinitrate of two different glyceryl trinitrate patches after 12-h usage in healthy volunteers. Bonn, R; Fritschi, E; Hutt, V; Pabst, G; Sauter, K, 1994) | 0.29 |
| "The pharmacokinetic characteristics and the bioavailability of glyceryl trinitrate (GTN, CAS 55-63-0) and of its main metabolities 1,2-glyceryl dinitrate (1,2-GDN, CAS 621-65-8) and 1,3-glyceryl dinitrate (1,3-GDN, CAS 623-87-0) during a single 24-h application of three strengths of a newly developed GTN transdermal patch (Epinitril) were investigated." | ( Plasma levels of glyceryl trinitrate and dinitrates during application of three strengths of a new glyceryl trinitrate transdermal patch. Caplain, H; Follet, M; Gualano, V; Rovati, LC; Santoro, A; Setnikar, I, 2000) | 0.31 |
| " GTN bioactivation measured as activation of purified soluble guanylate cyclase or release of NO in the presence of WT- or E268Q-ALDH2 was markedly potentiated by superoxide dismutase, suggesting that bioavailability of GTN-derived NO is limited by co-generation of superoxide." | ( Role of the general base Glu-268 in nitroglycerin bioactivation and superoxide formation by aldehyde dehydrogenase-2. Baral, PK; Beretta, M; Gorren, AC; Gruber, K; Koesling, D; Mayer, B; Russwurm, M; Schmidt, K; Wenzl, MV; Zeller, A, 2009) | 0.35 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " To compare the venodilatory potency of nitroglycerin and of 1,2-GDN and 1,3-GDN in vivo, cumulative dose-response curves were established in nine healthy volunteers by use of the dorsal hand vein compliance technique." | ( Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human veins. Benet, LZ; Blaschke, TF; Gumbleton, M; Haefeli, WE; Hoffman, BB, 1992) | 0.28 |
| " Nitroglycerin itself was virtually undetectable after the solution and tablet preparations; the metabolites were consistently detectable from a few minutes after dosing to 24 h later." | ( Pharmacokinetics of nitroglycerin and its metabolites after administration of sustained-release tablets. Curry, SH; Green, P; Kwon, HR, 1992) | 0.28 |
| " and oral dosing of GTN." | ( Pharmacokinetics and pharmacodynamics of glyceryl trinitrate and its two dinitrate metabolites in conscious dogs. Benet, LZ; Lee, FW; Metzler, CH; Salmonson, T, 1990) | 0.28 |
| " The establishment of a GDN plasma concentration-effect relationship together with the relatively high plasma levels of GDN achieved following GTN dosing supports the hypothesis that the GDNs contribute significantly to the hemodynamic effect observed with GTN." | ( Simultaneous pharmacodynamic modeling of the non-steady-state effects of three oral doses of 1,3-glyceryl dinitrate upon blood pressure in healthy volunteers. Benet, LZ; Gumbleton, M, 1993) | 0.29 |
| " This ratio is different from those obtained after iv bolus and oral dosing indicating that the biotransformation of GTN to 1,2-GDN and 1,3-GDN differs for each dosing route." | ( Pharmacokinetics and pharmacodynamics of nitroglycerin and its dinitrate metabolites in conscious dogs: intravenous infusion studies. Benet, LZ; Lee, FW; Salmonson, T, 1993) | 0.29 |
| "025 micrograms/kg) was given 50 min after beginning the GDN infusion and compared with plasma concentrations following a similar GTN dose in the absence of dosed GDNs." | ( Nitroglycerin dinitrate metabolites do not affect the pharmacokinetics and pharmacodynamics of nitroglycerin in the dog: a preliminary report. Benet, LZ; Hu, J; Lee, FW; Metzler, CH, 1993) | 0.29 |
| Class | Description |
|---|---|
| primary alcohol | A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it. |
| dinitroglycerol | A nitroglycerol carrying two nitro groups at unspecified positions. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| Muscle contraction | 77 | 21 |
| Smooth Muscle Contraction | 20 | 15 |
| Nitric Oxide Signaling Pathway | 12 | 8 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID613505 | Vasodilatory activity at endothelium denuded Wistar rat thoracic aorta assessed as relaxation of phenylephrine-induced contraction | 2011 | Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15 | New nitric oxide or hydrogen sulfide releasing aspirins. |
| AID613503 | Vasodilatory activity at endothelium denuded Wistar rat thoracic aorta assessed as relaxation of phenylephrine-induced contraction preincubated for 30 mins before phenylephrine challenge in presence of 1 uM soluble guanylate cyclase inhibitor H-[1,2,4]Oxa | 2011 | Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15 | New nitric oxide or hydrogen sulfide releasing aspirins. |
| AID352262 | Vasorelaxant activity in pig pulmonary artery by organ bath experiment | 2009 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11 | NO donors. Part 18: Bioactive metabolites of GTN and PETN--synthesis and vasorelaxant properties. |
| AID613137 | Antiaggregatory activity in plasma rich human platelets assessed as inhibition of collagen-induced platelet aggregation at 300 uM preincubated for 10 mins before collagen challenge measured 10 mins after stimulus addition | 2011 | Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15 | New nitric oxide or hydrogen sulfide releasing aspirins. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 19 (27.14) | 18.7374 |
| 1990's | 34 (48.57) | 18.2507 |
| 2000's | 15 (21.43) | 29.6817 |
| 2010's | 2 (2.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (9.90) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 11 (15.07%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 62 (84.93%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||